AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

AIM ImmunoTech Inc.

Major Shareholding Notification Aug 7, 2023

Preview not available for this file type.

Download Source File

SC 13D/A 1 d522685dsc13da.htm SC 13D/A SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

AIM IMMUNOTECH INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00901B105

(CUSIP Number)

Todd Deutsch

Ted D. Kellner

c/o Baker & Hostetler LLP

127 Public Square, Suite 2000

Cleveland, Ohio 44114

Attn: John J. Harrington

(216) 621-0200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 4, 2023

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §240.13d-1(e), §240.13d-1(f) or §240.13d-1(g), check the following box: ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 00901B105

1. Names of Reporting Persons Todd Deutsch
2. Check the Appropriate Box
if a Member of a Group (a) ☒ (b) ☐
3. SEC Use Only
4. Source of Funds (See
Instructions) PF
5. Check if Disclosure of
Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6. Citizenship or Place of
Organization United States of
America
Number of Shares Beneficially Owned by Each Reporting Person With Sole Voting Power 1,716,100
8. Shared Voting Power 0
9. Sole Dispositive Power 1,716,100
10. Shared Dispositive Power 0
11. Aggregate Amount Beneficially Owned by Each Reporting Person 1,716,100
12. Check if the Aggregate
Amount in Row (11) Excludes Certain Shares ☒
13. Percent of Class
Represented by Amount in Row (11) 3.5%(1)
14. Type of Reporting
Person IN

(1) Percentage ownership based on 48,408,295 shares outstanding as reported in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023.

CUSIP No. 00901B105

1. Names of Reporting Persons Ted D. Kellner
2. Check the Appropriate Box
if a Member of a Group (a) ☒ (b) ☐
3. SEC Use Only
4. Source of Funds (See
Instructions) PF
5. Check if Disclosure of
Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6. Citizenship or Place of
Organization United States of
America
Number of Shares Beneficially Owned by Each Reporting Person With Sole Voting Power 394,000
8. Shared Voting Power 1,049,000
9. Sole Dispositive Power 394,000
10. Shared Dispositive Power 1,049,000
11. Aggregate Amount Beneficially Owned by Each Reporting Person 1,443,000
12. Check if the Aggregate
Amount in Row (11) Excludes Certain Shares ☒
13. Percent of Class
Represented by Amount in Row (11) 3.0%(1)
14. Type of Reporting
Person IN

(1) Percentage ownership based on 48,408,295 shares outstanding as reported in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023.

SCHEDULE 13D

This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Schedule 13D (the “Initial Schedule 13D” and together with this Amendment No. 1, the “Schedule 13D”) filed with the Securities and Exchange Commission on July 27, 2023 by Todd Deutsch and Ted D. Kellner (the “Reporting Persons”) with respect to the Common Stock, par value $0.001 per share, of AIM ImmunoTech Inc. (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment No. 1 shall have the meanings set forth in the Initial Schedule 13D. This Amendment No. 1 amends Item 4 to the extent set forth below.

Item 4. Purpose of the Transaction

Item 4 is hereby supplemented as follows:

In accordance with the requirements of the Company’s bylaws, Mr. Kellner delivered on August 4, 2023 notice to the Company of his intent to nominate himself, Mr. Chioini and Mr. Deutsch for election to the Company’s board of directors at the 2023 annual meeting of stockholders.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

Date: August 7, 2023

TODD DEUTSCH
By: /s/ Todd Deutsch
TED D. KELLNER
By: /s/ Ted D. Kellner

Talk to a Data Expert

Have a question? We'll get back to you promptly.